ATRX and astrocytoma (excluding glioblastoma): Moreover, we have shown that in > 90% of cases, a combination of IDH, TP53, and codeletion status predicts the status of ATRX alterations relative to direct sequencing assessment, and that for the class of IDH-mutated astrocytomas there is no correlation between staining pattern and sequencing prediction.